FOLLOW US

Other Endocrine Disorders Research Updates

For Medical Professionals

Childhood cancer survivors are at increased risk for endocrine disorders into adulthood, with the cumulative incidence and prevalence increasing over time.
The U.S. Food and Drug Administration has approved Netspot , a radioactive probe designed for localization of somatostatin receptor positive neuroendocrine tumors in adult and pediatric patients during positron emission tomography imaging.
Women who have high levels of both testosterone and estrogen in midlife may be at greater risk of developing uterine fibroids than women with low levels of these hormones, according to a 13-year epidemiologic study published in the Journal of Clinical Endocrinology & Metabolism.
Overall prescription drug use increased 9% among U.S. adults between 1999 and 2012, according to data from the National Health and Nutrition Examination Survey.
Does exposure during adulthood to the standard therapeutic regimen for X-linked hypophosphatemia (XLH) of calcitriol and phosphate prevent or promote the development of enthesopathy?
Aldosterone is a new target for treating hypertension not only in patients with primary aldosterone, but also in a cohort of patients without primary aldosterone who were thought to have essential hypertension up to now.
Healthy men fed approximately 6,000 calories per day for 1 week experienced rapid weight gain as well as systemic and adipose tissue insulin resistance and oxidative stress, demonstrating for the first time in vivo a direct relationship between excessive nutrient intake and the development of insulin resistance.
EndocrineWeb provides a Q&A with A. Jay Cohen, MD summarizing his presentation made during AACE in May 2015. Here he discusses the challenges that arise during the transition from adolescent to adult care among patients with endocrine disorders.
The FDA has strengthened the warning regarding an increased risk for bone fractures and decreased bone mineral density for the type 2 diabetes medication canagliflozin (Invokana, Invokamet), and added a new item to Warnings and Precautions section and revised the Adverse Reactions section of the prescribing information.
While impaired renal function is considered a barrier to use of bisphosphonates, the researchers found that measures of renal function remained stable or improved slightly following use of pamidronate.
In the first study of its kind, researchers found that all 27 consecutive professional voice users (including professional operatic performers) who underwent neural monitored thyroid surgery were able to return to performance, researchers reported in a recent issue of Thyroid.
Exposure to urinary metabolites of the phthalate compound di-isononyl phthalate (DINP), which is increasingly used in the manufacturing of consumer products, was linked to an increased risk of high diabetes in adolescents enrolled in a cross-sectional analysis reported in the Journal of Clinical Endocrinology and Metabolism.
The National Cancer Institute (NCI)-supported precision medicine trial known as NCI-MATCH (Molecular Analysis for Therapy Choice) will begin enrollment in July 2015. The goal of the trial is to determine whether select cancer treatments are effective against specific molecular abnormalities, regardless of tumor type. Learn more about the trial and how patients can enroll.
Endocrine disrupting chemicals (EDCs) are chemicals that mimic, block, or interfere with hormones in the body. Increasing use of EDCs over the past 20 years may contribute to the growing number of people with infertility, diabetes, early onset of puberty in girls and early menopause in women, cancer, birth defects, and neurobehavioral disorders.
Merrimack Pharmaceuticals, Inc., has submitted a New Drug Application (NDA) for MM-398 (irinotecan liposome injection) in the treatment of patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based therapy. Merrimack has requested a priority review of the NDA.
Women with high levels of endocrine-disrupting chemicals experienced menopause 2 to 4 years earlier than women with lower levels of these chemicals, according to a cross-sectional study using data from using the National Health and Nutrition Examination Survey (NHANES). The findings were published in PLoS ONE.
Patients who have Cushing’s disease and receive mifepristone must undergo surveillance for evidence of tumor progression.
Researchers identified a variety of patient and tumor-specific characteristics that predict the postoperative growth rate of pituitary adenomas, according to a retrospective review published online ahead of print in the Journal of Clinical Endocrinology and Metabolism.
SHOW MAIN MENU
SHOW SUB MENU